For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Bioatla, Inc.

USPTO Granted Patents = 50

% Expired Patents = 2.0

CIPO Patents = 3

EPO Patents = 21

Forward Citations = 62

Loading Chart...

Loading Chart...

9 inventors (with patents filed for the assignee):

Jay Milton Short (48 out of 179 patents)

Hwai Wen Chang (32 out of 58 patents)

Gerhard Johann Frey (32 out of 87 patents)

4. Gregory Ian Frost (2 out of 8 patents)

5. James Joseph Onuffer, Jr (2 out of 7 patents)

6. Richard A Miller (2 out of 25 patents)

7. Emily Piccione Griffin (2 out of 7 patents)

8. William James Boyle (2 out of 30 patents)

9. Anirban Kundu (1 out of 1 patent)

Core Competencies:

Anti-EpCAM Antibodies

Chimeric Antigen Receptors

Anti-AXL Antibodies

Humanized Antibodies

Conditionally Active Proteins

Monoclonal Antibody Generation

Protein Evolution

Multi-Specific Monoclonal Antibodies

Anti-CTLA4 Antibodies

Diagnostics Using Antibodies

Anti-ROR2 Antibodies

50 patents: Sort by Forward Citations

1. 12742020 - CHIMERIC ANTIGEN RECEPTORS TO HER2 AND METHODS OF USE THEREOF (2026-09-22),

2. 12649793 - ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof (2026-06-09),

3. 12631650 - PROTEINS TARGETING ORTHOLOGS (2026-05-19),

4. 12595592 - Comprehensive monoclonal antibody generation (2026-04-07),

5. 12473360 - MULTI-SPECIFIC ANTIBODY CONSTRUCTS (2025-11-18),

6. 12427347 - Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof (2025-09-30),

7. 12187801 - Chimeric antigen receptors against AXL or ROR2 and methods of use thereof (2025-01-07),

8. 12110611 - Conditionally active biological proteins (2024-10-08),

9. 11976381 - Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts (2024-05-07),

10. 11897959 - Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof (2024-02-13),

11. 11879011 - Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof (2024-01-23),

12. 11859007 - Humanized anti-CD73 antibodies (2024-01-02),

13. 11851499 - Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-12-26),

14. 11834472 - Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-12-05),

15. 11773509 - Conditionally active polypeptides and methods of generating them (2023-10-03),

BioAtla, Inc. is a biotechnology company dedicated to developing novel antibody-based therapeutics for the treatment of various diseases. With a focus on conditionally active biologics (CABs), BioAtla aims to create next-generation antibody therapies with improved targeting, efficacy, and safety profiles. By leveraging their proprietary protein discovery, evolution, and engineering platform (Evolucix), BioAtla accelerates the development of innovative CAB candidates. Through strategic collaborations, BioAtla aims to expand its product pipeline, addressing unmet medical needs and making a positive impact on patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

50 Patents

#122 in San Diego, CA

#1,644 in California

#6,992 in US

#13,972 in the World

San Diego, CA, United States of America

Bioatla, Inc.

Forward Citations = 62

9 inventors:

Jay Milton Short (48 out of 179 patents)

Hwai Wen Chang (32 out of 58 patents)

Gerhard Johann Frey (32 out of 87 patents)

4. Gregory Ian Frost (2 out of 8 patents)

5. James Joseph Onuffer, Jr (2 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…